← Back

Wire · operational-macro

First Factor XIa inhibitor for stroke prevention in certain high-risk patients gains US FDA approval

Published

11 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at neuronewsinternational.com →

◆ Verified

Fusion42 · 11 November 2026 · Fusion42 review

The US FDA has approved Sunharbo (asundexian), the first Factor XIa inhibitor in the USA, for secondary stroke prevention in adults at high risk after a mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack when used with antiplatelet therapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You now face a new competitor with an FDA-approved stroke prevention drug that combines with antiplatelet therapy. If you develop treatments in cerebrovascular disease, this approval reshuffles market opportunities and patient protocols immediately.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalstroke-preventionfactor-xia-inhibitorbayerasundexian